Can we predict who which PsA pts will be radiographic progressors? Abs#449 identified 103 candidate biomarker peptides corresponding to 69 proteins that could ID progressors More data needed #ACR21 @RheumNow https://t.co/OLfPRNjTKV https://t.co/6UTn1J7nJH

• Identification of Serum Protein Biomarkers at Baseline to Distinguish Radiograp…

New treatments in #psoriaticarthritis Brepocitinib TYK 2/JAK 1 inhibitor had superior efficacy vs PBO in active PsA at Week 16, with improvements in more refractory domains over 52 weeks. Safety consistent with other JAKi @RheumNow #ACR21 Abstr#0488 https://t.co/ugsV7uRwro

• Efficacy and Safety of Brepocitinib (Tyrosine Kinase 2/Janus Kinase 1 Inhibitor…

Interesting study on immune cell profiling in PsA pts ⭐️variability in T cell sub-populations in PsA pts ⭐️no difference in lymphocyte cell populations before/after therapy Abs#0056 https://t.co/16PYxaxT2S #ACR21 @RheumNow https://t.co/dWaJr7hJ1p

• Peripheral Blood Immune Cell Profiling in Psoriatic Arthritis: Comparison of Pa…

#ACR21 Abst#0453. KEEPsAKE: Risankizumab (Skyrizi) monoclonal Ab inhibits IL23 by binding p19. ▶️150 mg RZB vs Placebo ⭐️RZB: higher ACR20/50/70, PASI90, HAQ-DI ⭐️Resolution of enthesitis, dactylitis. Improve fatigue, fxn ⭐️No safety signal https://t.co/bqQJ4Zr7o5 @Rheumnow https://t.co/2ZfGRs2GUd

• https://bit.ly/2ZWO0rV

KEEPsAKE trial 1 (DMARD-IR) and 2 (DMARD/biologic-IR) on risankizumab (IL23i) for PsA: 👉phase 3 DBRPCT 24 weeks 👉150 mg week 0,4, 16 weeks 👉improved ACR20,ACR50,ACR70 👉improved PASI90 👉improved HAQ-DI 👉no increased safety signals #ACR21 Abstr#0438 #Plenary @rheumnow https://t.co/ioIBXgV4Hi

Promising results of Risankizumab for #psoriaticarthritis 🔸Pts significantly achieved higher rates of ACR20, 50 and 70 response at wk 24 vs. placebo 🔸Well tolerated and showed no safety signals @RheumNow #ACR21 #ACRBest abs0453 https://t.co/TDSLEgF68g

Abst0453 #ACR21 @RheumNow integrated phase 2/3 trial results of il23 inhibitor Risankizumab (RZB) in PsA: significant improvement ACR20 at Week 24 (RZB 55.5% vs PBO 31.3%, P < 0.001), secondary endpoint met at HAQ DI, PASI, fatigue score& enthesitis. no new safety signals https://t.co/ZAVgswoXCf

RZB tx resulted in statistically greater improvements in signs/ symptoms of PsA vs PBO and was well tolerated w/ no new safety signals. Plenary Abs 0453 #ACR21 #RheumNow #ACRbest @RheumNow https://t.co/c9RJdWlmpO https://t.co/MDbdAhdnIy

• Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 24-Week Int…

New treatments in #psoriaticarthritis Deucravacitinib TYK2 inhibitor selectively mediates cytokine signaling, specific inflammatory pathways (eg, IL-23, IL-12, and Type I interferons) concomitant with clinical symptom improvement @RheumNow #ACR21 Abst#0490 https://t.co/7JZGa5R4eC

• Biomarker Changes with Selective Tyrosine Kinase 2 Inhibitor, Deucravacitinib, …

Dr Oster presenting on IL-23 inhibitor Risankizumab in PsA. No surprises here, it works. We need comparative efficacy trials! Abstr#0453 #ACR21 @RheumNow https://t.co/mj8TeCqEcg